Using Microphysiological System for the Development of Treatments for Joint Inflammation and Associated Cartilage Loss—A Pilot Study
Authors:
- Meagan J. MakarczykMMMeagan J. Makarczyk
- Sophie HinesSHSophie Hines
- Haruyo YagiHYHaruyo Yagi
- Zhong Alan LiZhong Alan Li
- Alyssa M. AgugliaAAAlyssa M. Aguglia
- Justin ZbikowskiJZJustin Zbikowski
- Anne-Marie PadgetAPAnne-Marie Padget
- Qi GaoQGQi Gao
- Bruce A. BunnellBruce A. Bunnell
- Stuart B. GoodmanStuart B. Goodman
- Hang LinHang Lin
Open Access
- 17 February 2023
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 13 (2) , 384
Abstract
Osteoarthritis (OA) is a painful and disabling joint disease affecting millions worldwide. The lack of clinically relevant models limits our ability to predict therapeutic outcomes prior to clinical trials, where most drugs fail. Therefore, there is a need for a model that accurately recapitulates the whole-joint disease nature of OA in humans. Emerging microphysiological systems provide a new opportunity. We recently established a miniature knee joint system, known as the miniJoint, in which human bone-marrow-derived mesenchymal stem cells (hBMSCs) were used to create an osteochondral complex, synovial-like fibrous tissue, and adipose tissue analogs. In this study, we explored the potential of the miniJoint in developing novel treatments for OA by testing the hypothesis that co-treatment with anti-inflammation and chondroinducing agents can suppress joint inflammation and associated cartilage degradation. Specifically, we created a “synovitis”-relevant OA model in the miniJoint by treating synovial-like tissues with interleukin-1β (IL-1β), and then a combined treatment of oligodeoxynucleotides (ODNs) suppressing the nuclear factor kappa beta (NF-κB) genetic pathway and bone morphogenic protein-7 (BMP-7) was introduced. The combined treatment with BMP-7 and ODNs reduced inflammation in the synovial-like fibrous tissue and showed an increase in glycosaminoglycan formation in the cartilage portion of the osteochondral complex. For the first time, this study demonstrated the potential of the miniJoint in developing disease-modifying OA drugs. The therapeutic efficacy of co-treatment with NF-κB ODNs and BMP-7 can be further validated in future clinical studies.Keywords
Funding Information
- National Institutes of Health (UG3/UH3 TR002136, UG3/UH3 TR003090, T32 EB001026, W81XWH2010902)
- U.S. Department of War (UG3/UH3 TR002136, UG3/UH3 TR003090, T32 EB001026, W81XWH2010902)
This publication has 41 references indexed in Scilit:
- Stem Cell-Based Microphysiological Osteochondral System to Model Tissue Response to Interleukin-1βMolecular Pharmaceutics, 2014
- Cartilage Tissue Engineering Application of Injectable Gelatin Hydrogel with In Situ Visible-Light-Activated Gelation Capability in Both Air and Aqueous SolutionTissue Engineering Part A, 2014
- Hypertrophic differentiation during chondrogenic differentiation of progenitor cells is stimulated by BMP-2 but suppressed by BMP-7Osteoarthritis and Cartilage, 2013
- Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritisBMC Musculoskeletal Disorders, 2010
- The Design and Fabrication of Three-Chamber Microscale Cell Culture Analog Devices with Integrated Dissolved Oxygen SensorsBiotechnology Progress, 2008
- Effects induced by BMPS in cultures of human articular chondrocytes: Comparative studiesGrowth Factors, 2008
- Differential requirements for IKKα and IKKβ in the differentiation of primary human osteoarthritic chondrocytesArthritis & Rheumatism, 2007
- OP-1/BMP-7 in cartilage repairInternational Orthopaedics, 2007
- Bone morphogenetic protein 7 (bmp-7) stimulates Proteoglycan synthesis in human osteoarthritic chondrocytes in vitroBiomedicine & Pharmacotherapy, 2006
- Regulation of NF‐κB Signaling by Decoy OligodeoxynucleotidesMicrobiology and Immunology, 2006